Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Karen Byth

Cutaneous Adverse Events (AEs) of Anti-Programmed Cell Death (PD)-1 Therapy in Patients With Metastatic Melanoma: A Single-Institution Cohort

Journal of the American Academy of Dermatology

Dermatology

2016

English

Oscillatory Pressure Wave Transmission From the Upper Airway to the Carotid Artery

Journal of Applied Physiology

English

Related publications

Diverse Cutaneous Adverse Eruptions Caused by Anti-Programmed Cell Death-1 (PD-1) and Anti-Programmed Cell Death Ligand-1 (PD-L1) Immunotherapies: Clinical Features and Management

Therapeutic Advances in Medical Oncology

Oncology

2018

English

632 Cutaneous Immune-Related Adverse Events in 1,857 Patients Treated With Anti-Pd-1 Therapy at an Academic Center

Journal of Investigative Dermatology

English

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies

English

Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients With Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?

English

2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(pd-L1) Inhibitor Therapy in HIV Patients With Advanced Cancer

Open Forum Infectious Diseases

Oncology

Neurology

2018

English

The Prognostic Role of Immune Checkpoint Markers Programmed Cell Death Protein 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) in a Large, Multicenter Prostate Cancer Cohort

Oncotarget

Oncology

2017

English

Anti-Programmed Cell Death Protein-1/Ligand-1 Therapy in Different Cancers

British Journal of Cancer

Cancer Research

Oncology

2015

English

Factors Influencing the Efficacy of Anti-Pd-1 Therapy in Chinese Patients With Advanced Melanoma

Journal of Oncology

Oncology

2019

English

Comment on ‘Efficacy and Toxicity of Treatment With the Anti-Ctla-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-Pd-1 Therapy’

British Journal of Cancer

Cancer Research

Oncology

2017

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Karen Byth

Cutaneous Adverse Events (AEs) of Anti-Programmed Cell Death (PD)-1 Therapy in Patients With Metastatic Melanoma: A Single-Institution Cohort

Oscillatory Pressure Wave Transmission From the Upper Airway to the Carotid Artery

Related publications

Diverse Cutaneous Adverse Eruptions Caused by Anti-Programmed Cell Death-1 (PD-1) and Anti-Programmed Cell Death Ligand-1 (PD-L1) Immunotherapies: Clinical Features and Management

632 Cutaneous Immune-Related Adverse Events in 1,857 Patients Treated With Anti-Pd-1 Therapy at an Academic Center

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies

Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients With Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?

2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(pd-L1) Inhibitor Therapy in HIV Patients With Advanced Cancer

The Prognostic Role of Immune Checkpoint Markers Programmed Cell Death Protein 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) in a Large, Multicenter Prostate Cancer Cohort

Anti-Programmed Cell Death Protein-1/Ligand-1 Therapy in Different Cancers

Factors Influencing the Efficacy of Anti-Pd-1 Therapy in Chinese Patients With Advanced Melanoma

Comment on ‘Efficacy and Toxicity of Treatment With the Anti-Ctla-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-Pd-1 Therapy’